Aoife Brennan - Jun 27, 2025 Form 4 Insider Report for Climb Bio, Inc. (CLYM)

Role
President and CEO, Director
Signature
/s/ Chandra Adams, as Attorney-in-Fact
Stock symbol
CLYM
Transactions as of
Jun 27, 2025
Transactions value $
-$25,154
Form type
4
Date filed
7/1/2025, 04:37 PM
Previous filing
Jun 12, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Brennan Aoife President and CEO, Director C/O CLIMB BIO, INC., 20 WILLIAM STREET, SUITE 145, WELLESLEY HILLS /s/ Chandra Adams, as Attorney-in-Fact 2025-07-01 0001714563

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLYM Common Stock Options Exercise +68.8K 68.8K Jun 27, 2025 Direct F1
transaction CLYM Common Stock Sale -$25.2K -20.6K -29.99% $1.22 48.1K Jun 30, 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLYM Restricted Stock Units Options Exercise $0 -68.8K -25% $0.00 206K Jun 27, 2025 Common Stock 68.8K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.
F2 The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $1.20 to $1.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F4 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F5 The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.

Remarks:

Exhibit Index: 24.1 - Power of Attorney